Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phenotypic Drug Susceptibility Testing
100%
High Burden
75%
Multidrug-resistant Tuberculosis (MDR-TB)
75%
Drug Susceptibility Testing
75%
Point-of-care
44%
Oral Drugs
40%
DS-TB
40%
1g Model Test
40%
Nearest Point
40%
Sputum
30%
Mycobacterium Tuberculosis (M. tb)
30%
Time-to-result
20%
Phenotypic Methods
20%
Decontamination Protocol
20%
Processing Protocol
20%
BPaL
20%
End TB Strategy
20%
Testing Process
20%
Low-middle Income Settings
20%
Delamanid
20%
Regular Powers
20%
Genotypic Methods
20%
Decontaminating
20%
Nonproprietary
20%
Re-culture
20%
Pretomanid
20%
Tailored Treatment
15%
Multidrug-resistant
15%
Biosafety Level
15%
Infectious Causes
15%
New Drugs
15%
Early Diagnosis
15%
Testing Protocol
15%
Clinical Providers
15%
Golden Standard
15%
Rapid Treatment
15%
Reduced Time
15%
Sputum Processing
15%
Drug-resistant Mycobacterium Tuberculosis
15%
TB Treatment
15%
High Flexibility
15%
Digestion Method
15%
Short Course
15%
Linezolid
15%
Ethambutol
15%
Liquid Medium
15%
Rifapentine
15%
Critical Concentration
15%
Low-middle Income Countries
15%
NIAID
15%
Drug Regimen
15%
Resource-limited Settings
15%
High Mortality
15%
GeneXpert
15%
XDR-TB
15%
Infectious Diseases
15%
Clofazimine
15%
Mycobacterium Tuberculosis Strains
15%
Drug Costs
15%
Power Supply
15%
Oral Agents
15%
Successful Treatment
15%
Medicine and Dentistry
Drug Sensitivity
75%
Drug Resistant Tuberculosis
75%
Health Care Cost
22%
Mycobacterium Tuberculosis
22%
Sputum
22%
Oral
22%
Isoniazid
15%
Delamanid
10%
Linezolid
10%
Rifapentine
10%
Pretomanid
10%
Ethambutol
7%
Infection
7%
Early Diagnosis
7%
Low and Middle Income Countries
7%
Clofazimine
7%
Pharmacology, Toxicology and Pharmaceutical Science
Drug Resistant Tuberculosis
75%
Mycobacterium Tuberculosis
56%
Isoniazid
37%
Rifapentine
25%
Pretomanid
25%
Delamanid
25%
Infection
18%
Ethambutol
18%
Linezolid
18%
Clofazimine
18%